Study of ZG005 in Patients With Advanced Solid Tumors
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
Advanced Solid Tumor
BIOLOGICAL: ZG005 for Injection
Objective response rate(ORR), Up to 2 years
Adverse Event (AE), Up to 2 years
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.